MLAB Share Price Performance
US$129.09
64.88 (101.04%)
9.9% overvalued intrinsic discount
US$117.50
Fair Value
Price US$129.09
AnalystConsensusTarget US$117.50
AnalystLowTarget US$94.00
Fair ValueUS$117.50
Share Pricen/a
New Narrative • Aug 25
Mesa Laboratories, Inc. Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 6 Fair Values set on narratives written by author
MLAB Community Narratives
AN
Fair Value
·Fair Value US$117.5 9.9% overvalued intrinsic discount
Recurring Quality Control Demand And Cost Discipline Will Support Future Earnings Stability
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value US$94 37.3% overvalued intrinsic discount
Execution Fixes In Regulated Controls Will Shape Future Earnings Stability And Balance Sheet Strength
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Recurring Quality Control Demand And Cost Discipline Will Support Future Earnings Stability
Mesa Laboratories sells the behind-the-scenes tools and supplies that pharma and medical device companies rely on to meet strict quality rules, creating demand that can be hard to switch away from. A push to tighten costs and launch a next-generation testing platform could make results steadier over time—but execution and product rollout timing still matter.Read more
AN
US$117.5
9.9% overvalued intrinsic discount
Fair Value
Revenue
4.31% p.a.
Profit Margin
15.65%
Future PE
19.68x
Price in 2029
US$150
Execution Fixes In Regulated Controls Will Shape Future Earnings Stability And Balance Sheet Strength
Mesa Laboratories sells tools that regulated drug and industrial makers rely on, but ongoing delivery problems could keep results lumpy and test customer loyalty. The key question is whether fixing operations and launching a new Gyrolab system can steady the business while it also works down debt.Read more
AN
US$94
37.3% overvalued intrinsic discount
Fair Value
Revenue
4.72% p.a.
Profit Margin
3.5%
Future PE
67.09x
Price in 2029
US$120.21
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
Recurring Quality Control Demand And Cost Discipline Will Support Future Earnings Stability
Fair Value: US$117.5 9.9% overvalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Execution Fixes In Regulated Controls Will Shape Future Earnings Stability And Balance Sheet Strength
Fair Value: US$94 37.3% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Mesa Laboratories, Inc. Key Details
About MLAB
- Founded
- 1982
- Employees
- 717
- CEO
- WebsiteView website
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides sterility assurance testing and laboratory services to the dental and pharmaceutical industries. The Biopharmaceutical Development segment develops, manufactures, sells, and services automated systems for protein analysis (immunoassays) and peptide synthesis solutions. Its Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for hereditary disease screenings, pharmacogenetics, oncology related applications, and toxicology research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; and PurePep Symphony and Chorus instruments for peptide synthesis. Its Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as renal care, gas flow, environmental and process monitoring, and torque testing in pharmaceutical, laboratory, medical device, manufacturing, industrial, and environmental applications. This segment’s products include continuous monitoring systems, data loggers, and torque testing systems under the DialyGuard, DryCal, DataTrace, and ViewPoint brands. Mesa Laboratories, Inc. was incorporated in 1982 and is headquartered in Lakewood, Colorado.
